What is the medical insurance reimbursement price of dasatinib in 2024?

Dasatinib is a highly effective tyrosine kinase inhibitor, mainly used to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib mesylate. CML is a clonal disease originating from bone marrow hematopoietic stem cells and is characterized by the BCR-ABL fusion gene formed by translocation of chromosome 9 or 22, resulting in uncontrolled cell proliferation. Dasatinib inhibits the tyrosine kinase activity of BCR-ABL protein and blocks its downstream signaling, thereby inhibiting the proliferation and survival of leukemia cells and effectively controlling the progression of CML.

In addition to its significant efficacy againstCML, dasatinib has also shown potential in the treatment of a number of other hematological malignancies. For example, it can be used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), providing a new treatment option for these patients. In addition, dasatinib has shown efficacy in diseases such as myelodysplastic syndrome (MDS) and systemic mastocytosis (SM) in some clinical trials.

The therapeutic advantage of dasatinib lies in its high potency and inhibition of multiple kinase targets, which makes it uniquely advantageous in treating certain patients who are resistant or intolerant to imatinib. However, dasatinib may also cause some side effects, such as bone marrow suppression, gastrointestinal reactions, etc. Therefore, it is necessary to strictly follow medical instructions when using it, and conduct regular monitoring of blood routine and biochemical indicators to ensure the safety and effectiveness of treatment.

Dasatinib has been launched in the country and has been included in Class B medical insurance reimbursement items. In China, you can choose the original research version or the domestic imitation version. The price of the former 50mg*60 tablets after reimbursement is close to 9,000 yuan, and the latter 50mg*7 tablets is about 500 yuan. In India, Bangladesh and other countries, there are a variety of imitation versions on the market. The price of 50mg*60 tablets is in the range of 600-1,000 yuan, which is relatively cost-effective.

In short, dasatinib, as an important anti-tumor drug, provides a new option for the treatment of hematological malignancies such as CML, and its application prospects in clinical practice are broad.